Amundi Pioneer Asset Management Inc. cut its stake in Zoetis Inc. (NYSE:ZTS) by 44.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,907,512 shares of the company’s stock after selling 1,551,218 shares during the period. Amundi Pioneer Asset Management Inc. owned 0.40% of Zoetis worth $315,693,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Jeppson Wealth Management LLC acquired a new stake in Zoetis in the 3rd quarter worth approximately $25,000. Graves Light Private Wealth Management Inc. acquired a new stake in Zoetis in the 4th quarter worth approximately $31,000. Arlington Partners LLC purchased a new position in Zoetis during the 4th quarter worth approximately $32,000. Hoover Financial Advisors Inc. purchased a new position in Zoetis during the 4th quarter worth approximately $32,000. Finally, Annapolis Financial Services LLC purchased a new position in Zoetis during the 4th quarter worth approximately $33,000. Institutional investors own 92.50% of the company’s stock.
Shares of NYSE ZTS opened at $157.88 on Thursday. The firm has a market cap of $75.02 billion, a PE ratio of 46.85, a PEG ratio of 4.35 and a beta of 0.71. The firm has a fifty day moving average of $155.41 and a 200 day moving average of $160.68. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 3.47. Zoetis Inc. has a one year low of $121.50 and a one year high of $176.64.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 1st. Shareholders of record on Wednesday, April 21st will be paid a dividend of $0.25 per share. The ex-dividend date is Tuesday, April 20th. This represents a $1.00 annualized dividend and a yield of 0.63%. Zoetis’s dividend payout ratio (DPR) is presently 27.47%.
A number of equities analysts have issued reports on ZTS shares. Credit Suisse Group raised their price target on shares of Zoetis from $197.00 to $203.00 in a research report on Wednesday, February 17th. Bank of America raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 price target for the company in a research report on Monday, March 15th. Finally, Raymond James raised shares of Zoetis from a “market perform” rating to an “outperform” rating and set a $166.00 target price for the company in a report on Monday, March 15th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $170.08.
In other Zoetis news, EVP Robert Edward Kelly sold 2,054 shares of Zoetis stock in a transaction on Thursday, February 11th. The shares were sold at an average price of $161.15, for a total transaction of $331,002.10. Following the sale, the executive vice president now owns 10,029 shares of the company’s stock, valued at approximately $1,616,173.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert W. Scully bought 7,590 shares of the stock in a transaction on Friday, February 19th. The shares were acquired at an average cost of $164.68 per share, for a total transaction of $1,249,921.20. The disclosure for this purchase can be found here. Insiders own 0.17% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: Basic Economics
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.